Wu Wei, Sun Yanting, Li Zhaoting, Yao Yuntai
Department of Anesthesiology, Baoji High-Tech Hospital, Shaanxi, China.
Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Medicine (Baltimore). 2025 Jul 25;104(30):e43567. doi: 10.1097/MD.0000000000043567.
OBJECTIVE: Ciprofol (HSK-3486), a novel intravenous anesthetic with structural similarities to propofol, has shown promising pharmacokinetic (PK) and pharmacodynamic (PD) profiles; however, clinical data regarding its efficacy and safety remain limited. Because research on ciprofol is still in its infancy, this study uses bibliometric methods to examine the published literature and to highlight research trends, key topics, and future directions for its clinical applications. METHODS: We searched the Web of Science Core Collection (WoSCC) for English-language articles and reviews on ciprofol published from 2017 - the year it was first reported - through August 28, 2024. Two authors independently screened titles and abstracts for eligibility, discrepancies were resolved in consultation with a senior reviewer. The data, including publication details and citation metrics, were extracted and organized for analysis. We visualized the results with CiteSpace, GraphPad Prism, and Microsoft Excel. RESULTS: A total of 62 studies were included. Annual publications rose by 50% from 2021 to 2022 and by 83% from 2022 to 2023. China dominated the field, contributing 59 articles (95.16% of the total). Sichuan University and Liu X. were the most prolific institution and author, respectively. BMC Anesthesiology, Drug Design, Development and Therapy, Frontiers in Pharmacology, and Journal of Clinical Anesthesia were the 4 leading journals publishing ciprofol research. Frontiers in Pharmacology received the most citations (n = 71) and achieved an H-index of 4. Anesthesiology carried the highest 2022 impact factor (9.1), whereas Anesthesia and Analgesia accrued 48 citations. Safety, pharmacokinetics, and anesthesia were the most frequently studied aspects, whereas "critically ill patients," "injection," and "pain" emerged as recent research hotspots. Temporal analysis showed that key terms shifted from "pharmacokinetics" in 2021 to "general anesthesia" by 2022, while themes such as "critically ill patients" remained consistently relevant. CONCLUSION: This bibliometric analysis provides a comprehensive overview of ciprofol research, identifies key contributors, and reveals critical insights and gaps in the literature. Our findings underscore ciprofol's safety, efficacy, and optimal clinical use while highlighting current hotspots and challenges that should guide future research.
目的:环泊酚(HSK-3486)是一种新型静脉麻醉药,其结构与丙泊酚相似,已显示出有前景的药代动力学(PK)和药效学(PD)特征;然而,关于其有效性和安全性的临床数据仍然有限。由于环泊酚的研究仍处于起步阶段,本研究采用文献计量学方法来审视已发表的文献,并突出其临床应用的研究趋势、关键主题和未来方向。 方法:我们在科学网核心合集(WoSCC)中检索了2017年(环泊酚首次报道的年份)至2024年8月28日发表的关于环泊酚的英文文章和综述。两位作者独立筛选标题和摘要以确定是否符合纳入标准,如有分歧则与一位资深审稿人协商解决。提取并整理包括发表细节和引用指标在内的数据进行分析。我们使用CiteSpace、GraphPad Prism和Microsoft Excel对结果进行可视化展示。 结果:共纳入62项研究。从2021年到2022年年度发表量增长了50%,从2022年到2023年增长了83%。中国在该领域占主导地位,贡献了59篇文章(占总数的95.16%)。四川大学和刘X分别是发文量最多的机构和作者。《BMC麻醉学》《药物设计、开发与治疗》《药理学前沿》和《临床麻醉学杂志》是发表环泊酚研究的4种主要期刊。《药理学前沿》获得的引用次数最多(n = 71),H指数为4。《麻醉学》的2022年影响因子最高(9.1),而《麻醉与镇痛》获得了48次引用。安全性、药代动力学和麻醉是研究最频繁的方面,而“危重症患者”“注射”和“疼痛”成为近期的研究热点。时间分析表明,关键词从2021年的“药代动力学”转变为2022年的“全身麻醉”,而“危重症患者”等主题一直都很相关。 结论:这项文献计量学分析全面概述了环泊酚的研究情况,确定了关键贡献者,并揭示了文献中的关键见解和空白。我们的研究结果强调了环泊酚的安全性、有效性和最佳临床应用,同时突出了当前的热点问题和挑战,这些应指导未来的研究。
Medicine (Baltimore). 2025-7-25
Front Oncol. 2025-6-30
Quant Imaging Med Surg. 2025-7-1
Cochrane Database Syst Rev. 2018-1-16
Eur Rev Med Pharmacol Sci. 2022-7